Markers For Determination Of Patient Responsiveness
|Document №||Publication date||Filed Date||Application №|
|20160054320||February 25, 2016||April 4, 2014||14/781885|
Compositions and methods are provided for classification of individuals suffering from a demyelinating disease into groups that are informative of the individual’s responsiveness or lack of responsiveness to treatment with a J3-interferon (IFNJ3) acting therapy. In particular, it is shown that the effective immunomodulatory treatment of demyelinating disease with IFNJ3 is associated with an increase in circulating transitional B cells in the patient. Diseases of interest include without limitation inflammatory demyelinating diseases of the central nervous system, e.g. multiple sclerosis, neuromyelitis optica (NMO), experimental autoimmune encephalitis (EAE), acute disseminated encephalomyelitis (ADEM), etc.